Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Interim results from a muticenter prospective cohort study
第一作者单位:[1]Fudan Univ, Huashan Hosp, Canc Metastasis Inst, Dept Gen Surg, Shanghai, Peoples R China[2]Sichuan Univ, Huaxi Hosp, Dept Liver Surg, Chengdu, Sichuan, Peoples R China[3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China[4]Tianjin Canc Hosp, Dept Hapatobiliary Surg, Tianjin, Peoples R China[5]Fujian Med Univ, Dept Hepatobiliary Surg, Mengchao Hepatobiliary Hosp, Fuzhou, Peoples R China[6]Nanjing Med Univ, Chinese Acad Med Sci, Hepatobiliary Ctr, Key Lab Liver Transplantat,Affiliated Hosp 1, Nanjing, Peoples R China[7]Guangxi Med Univ, Canc Hosp, Dept Hepatopancreatobiliary Surg, Nanning, Peoples R China[8]Ningbo Univ, Ningbo Med Ctr, Dept Hepatopancreatobiliary Surg, LiHuiLi Hosp, Ningbo, Peoples R China[9]Zhejiang Univ, Dept Hepatopancreatobiliary Surg, Affiliated Hosp 1, Hangzhou, Peoples R China
推荐引用方式(GB/T 7714):
Chen Jin-hong,Lu Lu,Wen Tian-Fu,et al.Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Interim results from a muticenter prospective cohort study[J].JOURNAL OF CLINICAL ONCOLOGY.2020,38(15):doi:10.1200/JCO.2020.38.15_suppl.4580.
APA:
Chen, Jin-hong,Lu, Lu,Wen, Tian-Fu,Huang, Zhi-Yong,Zhang, Ti...&Qin, Lun-xiu.(2020).Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Interim results from a muticenter prospective cohort study.JOURNAL OF CLINICAL ONCOLOGY,38,(15)
MLA:
Chen, Jin-hong,et al."Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Interim results from a muticenter prospective cohort study".JOURNAL OF CLINICAL ONCOLOGY 38..15(2020)